Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...
This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...
The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...
Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases (AASLD), ...
Poviztra (semaglutide injection 2.4 mg) is the second brand of Wegovy, Novo Nordisk’s blockbuster obesity medication, which ...
The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...
() -Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss ...
rocketcitynow.com on MSN
Alabama AG orders temporary shutdown of Cullman IV clinic due to unsafe weight loss drugs
Alabama Attorney General Steve Marshall has shut down a Cullman IV clinic after allegations it gave patients unsafe, research ...
As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra in India.
Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's monthly FluidCrystal® semaglutide formulation, ...
Dr Reddy's Labs may face an 8-12 month delay in launching its semaglutide generic in Canada after receiving a non-compliance ...
Dr Reddy’s shares drop over 5% following a regulatory setback for its weight-loss drug in Canada, risking future revenues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback